Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00024037 · ClinicalTrials.gov registry record · Phase 2

Laser Therapy in Preventing Oral Mucositis in Patients Undergoing Bone Marrow Transplantation

A Phase 2 study of Oral Complications, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00024037 is a Phase 2 study of Oral Complications that has completed, run by Fred Hutchinson Cancer Center. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00024037, a Phase 2 study of Oral Complications, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

RATIONALE: Laser therapy may reduce the severity of symptoms and speed healing of oral mucositis. It is not yet known if laser therapy is effective in preventing oral mucositis. PURPOSE: Randomized phase II/III trial to determine the effectiveness of laser therapy in preventing oral mucositis in patients who are undergoing bone marrow transplantation.

Conditions Studied

Interventions

  • PROCEDURE management of therapy complications

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Start Date 1995-04
Est. Completion 2002-12
Phase Phase 2

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT00024037

The ClinicalTrials.gov registry entry for NCT00024037 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Oral Complications appearing as the primary indexed condition, and to 1 intervention - of which management of therapy complications is the first listed.

NCT00024037 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00024037 about?

NCT00024037 is a clinical study titled "Laser Therapy in Preventing Oral Mucositis in Patients Undergoing Bone Marrow Transplantation". RATIONALE: Laser therapy may reduce the severity of symptoms and speed healing of oral mucositis. It is not yet known if laser therapy is effective in preventing oral mucositis. PURPOSE: Randomized phase II/III trial to determine the effectiveness of laser therapy in preventing oral mucositis in pa...

What is the current status of trial NCT00024037?

This trial is currently completed. It is a Phase 2 study. The study started on 1995-04. Estimated completion is 2002-12.

What conditions does trial NCT00024037 study?

This clinical trial studies the following conditions: Oral Complications.

What interventions are being tested in trial NCT00024037?

The interventions under investigation include: management of therapy complications (PROCEDURE).

Who is sponsoring clinical trial NCT00024037?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00024037 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Oral Complications

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.